Type 2 biomarkers associated with dupilumab efficacy in patients with uncontrolled, moderate-to-severe asthma enrolled in the phase 3 study LIBERTY ASTHMA QUEST

Samankaltaisia teoksia

• Dupilumab reduces severe exacerbation rate and improves lung function in adolescent patients with uncontrolled, moderate-to-severe asthma: from the Liberty Asthma Quest study
  Tekijä: Maspero, J, et al.
  Julkaistu: (2018)
• Dupilumab efficacy in uncontrolled, moderate-to-serve allergic asthma in the phase 3 liberty asthma quest study
  Tekijä: Castro, M, et al.
  Julkaistu: (2018)
• Dupilumab reduces risk of severe exacerbations and improves FEV1 in patients on both high- and medium dose ICS with uncontrolled, moderate-to-severe asthma from the phase 3 LIBERTY ASTHMA QUEST Study
  Tekijä: Pavord, I, et al.
  Julkaistu: (2018)
• A randomized, controlled phase 3 study, Liberty Asthma Quest, evaluating the efficacy and safety of dupilumab in uncontrolled moderate-to-severe asthma
  Tekijä: Castro, M, et al.
  Julkaistu: (2018)
• Dupilumab efficacy and safety in Japanese patients with uncontrolled, moderate-to-severe asthma in the phase 3 LIBERTY ASTHMA QUEST study
  Tekijä: Yuji Tohda, et al.
  Julkaistu: (2020-10-01)